Continuing enasidenib treatment for patients with mutant- IDH2 (m IDH2) relapsed or refractory acute myeloid leukemia (R/R AML) with stable disease may result in improved survival and responses over time Meeting Abstract
| Authors: | Stein, E. M.; Stone, R. M.; Pollyea, D. A.; Roboz, G. J.; Altman, J. K.; DiNardo, C. D.; de Botton, S.; Tu, N.; Swern, A. S.; Tosolini, A.; Gupta, I.; Agresta, S. V.; Fathi, A. T. |
| Abstract Title: | Continuing enasidenib treatment for patients with mutant- IDH2 (m IDH2) relapsed or refractory acute myeloid leukemia (R/R AML) with stable disease may result in improved survival and responses over time |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419403122 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.1299.1299 |
| Notes: | Meeting Abstract: 1299 -- Source: Wos |
